Editas Long Term Debt vs Total Revenue Analysis

EDIT Stock  USD 2.10  0.13  5.83%   
Editas Medicine financial indicator trend analysis is much more than just examining Editas Medicine latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Editas Medicine is a good investment. Please check the relationship between Editas Medicine Long Term Debt and its Total Revenue accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Editas Medicine. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
For more information on how to buy Editas Stock please use our How to Invest in Editas Medicine guide.

Long Term Debt vs Total Revenue

Long Term Debt vs Total Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Editas Medicine Long Term Debt account and Total Revenue. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Editas Medicine's Long Term Debt and Total Revenue is 0.54. Overlapping area represents the amount of variation of Long Term Debt that can explain the historical movement of Total Revenue in the same time period over historical financial statements of Editas Medicine, assuming nothing else is changed. The correlation between historical values of Editas Medicine's Long Term Debt and Total Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Long Term Debt of Editas Medicine are associated (or correlated) with its Total Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Revenue has no effect on the direction of Long Term Debt i.e., Editas Medicine's Long Term Debt and Total Revenue go up and down completely randomly.

Correlation Coefficient

0.54
Relationship DirectionPositive 
Relationship StrengthWeak

Long Term Debt

Long-term debt is a debt that Editas Medicine has held for over one year. Long-term debt appears on Editas Medicine balance sheet and also includes long-term leases. The most common forms of long term debt are bonds payable, long-term notes payable, mortgage payable, pension liabilities, and lease liabilities. In the corporate world, long-term debt is generally used to fund big-ticket items, such as machinery, buildings, and land. The total of long-term debt reported on Editas Medicine balance sheet is the sum of the balances of all categories of long-term debt. Debt that is not due within the current year and is often considered to be financing activities that are to be repaid over several years.

Total Revenue

Total revenue comprises all receipts Editas Medicine generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.
Most indicators from Editas Medicine's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Editas Medicine current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Editas Medicine. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
For more information on how to buy Editas Stock please use our How to Invest in Editas Medicine guide.Enterprise Value is likely to gain to about 921.9 M in 2024, whereas Selling General Administrative is likely to drop slightly above 57.9 M in 2024.
 2021 2022 2023 2024 (projected)
Total Operating Expenses218.7M245.7M247.3M168.4M
Cost Of Revenue5.1M6.3M177.7M186.5M

Editas Medicine fundamental ratios Correlations

0.120.70.940.950.810.91-0.81-0.830.860.840.880.710.820.990.950.580.780.880.750.890.990.610.950.660.85
0.120.050.03-0.120.110.050.19-0.040.060.41-0.010.150.160.130.280.75-0.07-0.010.630.040.160.07-0.1-0.040.53
0.70.050.760.620.670.59-0.46-0.820.690.50.640.570.690.660.710.490.570.790.620.630.680.260.640.310.52
0.940.030.760.890.810.94-0.82-0.860.950.80.850.660.760.90.930.520.710.880.710.930.920.640.910.720.82
0.95-0.120.620.890.660.88-0.81-0.830.820.690.930.720.830.940.870.310.820.890.510.880.910.51.00.590.68
0.810.110.670.810.660.74-0.77-0.560.680.780.470.380.410.810.710.730.510.60.830.620.880.780.660.740.73
0.910.050.590.940.880.74-0.84-0.810.940.810.810.660.720.880.90.470.570.840.660.970.890.750.880.740.84
-0.810.19-0.46-0.82-0.81-0.77-0.840.57-0.7-0.81-0.6-0.37-0.49-0.82-0.68-0.35-0.54-0.65-0.52-0.74-0.84-0.81-0.8-0.87-0.66
-0.83-0.04-0.82-0.86-0.83-0.56-0.810.57-0.87-0.59-0.88-0.9-0.93-0.77-0.88-0.36-0.64-0.99-0.54-0.89-0.77-0.36-0.85-0.41-0.67
0.860.060.690.950.820.680.94-0.7-0.870.70.850.70.760.810.920.460.610.870.640.950.820.570.850.610.78
0.840.410.50.80.690.780.81-0.81-0.590.70.570.460.590.850.810.770.480.630.860.720.890.770.690.780.92
0.88-0.010.640.850.930.470.81-0.6-0.880.850.570.790.910.840.890.260.840.90.450.880.780.270.940.420.66
0.710.150.570.660.720.380.66-0.37-0.90.70.460.790.920.650.790.320.570.890.450.740.640.260.750.270.62
0.820.160.690.760.830.410.72-0.49-0.930.760.590.910.920.780.870.350.730.940.510.80.740.220.850.330.67
0.990.130.660.90.940.810.88-0.82-0.770.810.850.840.650.780.910.60.790.830.750.830.990.60.930.670.82
0.950.280.710.930.870.710.9-0.68-0.880.920.810.890.790.870.910.620.690.890.780.920.910.540.890.550.89
0.580.750.490.520.310.730.47-0.35-0.360.460.770.260.320.350.60.620.270.360.970.380.660.540.320.450.8
0.78-0.070.570.710.820.510.57-0.54-0.640.610.480.840.570.730.790.690.270.70.430.570.720.140.810.460.49
0.88-0.010.790.880.890.60.84-0.65-0.990.870.630.90.890.940.830.890.360.70.540.890.820.410.90.480.68
0.750.630.620.710.510.830.66-0.52-0.540.640.860.450.450.510.750.780.970.430.540.580.810.630.520.570.89
0.890.040.630.930.880.620.97-0.74-0.890.950.720.880.740.80.830.920.380.570.890.580.840.590.90.580.79
0.990.160.680.920.910.880.89-0.84-0.770.820.890.780.640.740.990.910.660.720.820.810.840.690.90.710.86
0.610.070.260.640.50.780.75-0.81-0.360.570.770.270.260.220.60.540.540.140.410.630.590.690.50.860.72
0.95-0.10.640.911.00.660.88-0.8-0.850.850.690.940.750.850.930.890.320.810.90.520.90.90.50.590.7
0.66-0.040.310.720.590.740.74-0.87-0.410.610.780.420.270.330.670.550.450.460.480.570.580.710.860.590.68
0.850.530.520.820.680.730.84-0.66-0.670.780.920.660.620.670.820.890.80.490.680.890.790.860.720.70.68
Click cells to compare fundamentals

Editas Medicine Account Relationship Matchups

Editas Medicine fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets508.9M572.6M677.5M514.3M499.2M395.9M
Short Long Term Debt Total29.1M26.1M26.4M43.9M36.5M36.1M
Other Current Liab24.8M17.2M9.9M20.2M22.4M23.5M
Total Current Liabilities60.0M58.2M46.9M60.1M63.2M40.9M
Total Stockholder Equity262.4M393.6M553.6M360.7M349.1M239.8M
Other Liab163.2M101.5M60.9M60.7M69.8M71.4M
Property Plant And Equipment Net39.6M39.1M43.3M59.2M45.7M35.0M
Net Debt(209.1M)(113.5M)(177.1M)(97.6M)(87.1M)(91.5M)
Retained Earnings(549.2M)(665.2M)(857.7M)(1.1B)(1.2B)(1.2B)
Accounts Payable5.8M6.4M5.1M9.5M8.3M5.3M
Cash238.2M139.7M203.5M141.5M123.7M146.9M
Non Current Assets Total45.0M153.5M170.2M157.6M158.3M82.0M
Non Currrent Assets Other107K4.7M6.8M5.3M8.6M9.0M
Other Assets1.7M4.7M6.8M5.3M6.0M6.3M
Cash And Short Term Investments457.1M511.8M619.9M437.4M323.1M338.9M
Common Stock Shares Outstanding50.0M58.6M67.6M68.7M76.0M49.3M
Liabilities And Stockholders Equity508.9M572.6M677.5M514.3M499.2M395.9M
Non Current Liabilities Total186.5M120.8M77.0M93.5M86.8M115.2M
Other Current Assets6.3M21.9M14.4M7.3M7.5M6.1M
Other Stockholder Equity811.5M1.1B1.4B1.4B1.6B1.7B
Total Liab246.4M179.0M123.8M153.6M150.1M156.1M
Property Plant And Equipment Gross39.6M39.1M58.8M80.7M72.0M41.4M
Total Current Assets463.8M419.1M507.3M356.8M340.8M314.0M
Accumulated Other Comprehensive Income107K(46K)(493K)(3.6M)198K207.9K
Property Plant Equipment39.6M14.0M17.1M15.6M17.9M23.1M
Net Tangible Assets262.4M393.6M553.6M360.7M414.8M250.7M
Current Deferred Revenue23.5M20.9M11.3M8.2M9.5M14.2M
Net Receivables418K6.0M267K5.1M10.2M10.7M
Short Term Debt5.8M13.6M20.6M22.2M24.3M14.0M
Short Term Investments219.0M262.4M296.3M202.8M199.5M195.2M
Capital Surpluse811.5M1.1B1.4B1.4B1.7B854.8M
Retained Earnings Total Equity(549.2M)(665.2M)(857.7M)(1.1B)(970.3M)(921.8M)
Capital Lease Obligations29.1M26.1M26.4M43.9M36.5M36.2M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Editas Stock Analysis

When running Editas Medicine's price analysis, check to measure Editas Medicine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Editas Medicine is operating at the current time. Most of Editas Medicine's value examination focuses on studying past and present price action to predict the probability of Editas Medicine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Editas Medicine's price. Additionally, you may evaluate how the addition of Editas Medicine to your portfolios can decrease your overall portfolio volatility.